로딩 중…
지수 로딩 중…
ViGenCell Inc.
308080· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩7,090-2.74%
2026-06-19
Price Chart
ViGenCell Inc.+140.75%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 145.34B KRW |
| Revenue | 22.7M KRW |
| Net Income | -6.12B KRW |
| Total Assets | 50.26B KRW |
| Net Assets | 43.72B KRW |
| Employees | 63 |
| Value | |
| P/B | 3.32x |
| FCF Yield | -9.51% |
| Profitability | |
| ROE | -14.00% |
| ROA | -12.17% |
| Op. Margin | -75453.12% |
| Revenue Growth | -91.87% |
| Financial Health | |
| Debt Ratio | 114.96% |
| Total Debt | 0 KRW |
| FCF | -13.82B KRW |
| Cash | 5.11B KRW |
| Current Ratio | 18.99x |
| Performance | |
| 1Y Return | 140.75% |
| 1M Return | -23.93% |
| From 52W High | -59.16% |
| 1Y MDD | -68.70% |
| Trading | |
| Volume | 279,426 shares |
| Foreign Own. | 1.22% |
| Per Share | |
| EPS | -798 KRW |
| BPS | 2,007 KRW |
Company Info
Established in 2013, the company is a bio venture specializing in pharmaceutical research and development and immune cell therapy development. Based on HLA research from The Catholic University of Korea College of Medicine, it develops immunotherapies using human blood-derived immune cells and is a cell therapy specialist with domestic clinical trial experience in antigen-specific killer T-cell research. Utilizing its ViTier platform technology, the company is developing treatments for NK/T-cell lymphoma and acute myeloid leukemia. Vaxcell-Bio was established in 2013 and is headquartered in Seoul-si, Geumcheon-gu.